Literature DB >> 20011423

Medical management of Crohn's disease.

Paul A Feldman1, Daniel Wolfson, Jamie S Barkin.   

Abstract

The clinical course of Crohn's disease (CD) is characterized by unpredictable phases of disease activity and quiescence. The majority of CD patients experience mild to moderate disease or are in clinical remission over significant periods during the course of their disease. These patients can be treated conservatively with 5-aminosalicylates or budesonide depending on the disease location. Those patients with more severe forms of the disease who require corticosteroids should be treated more aggressively with early introduction of immunomodulator and/or biologic therapy, which may help to prevent the complications associated with CD. It has been suggested that therapies directed at mucosal healing may favorably modify the natural history of CD. As newer, more effective medications become available and new therapeutic approaches are introduced (top-down therapy), mucosal healing, and not solely clinical remission, may well become the preferred treatment objective.

Entities:  

Keywords:  Crohn's disease; medical management

Year:  2007        PMID: 20011423      PMCID: PMC2780222          DOI: 10.1055/s-2007-991026

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  133 in total

Review 1.  Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?

Authors:  J R Bebb; R P Logan
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

Review 2.  Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

Authors:  William J Sandborn; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2002-12       Impact factor: 10.864

3.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

Review 4.  Factors affecting recurrence after surgery for Crohn's disease.

Authors:  Takayuki Yamamoto
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

5.  Second trial of mesalamine therapy in the treatment of active Crohn's disease.

Authors:  J Singleton
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids.

Authors:  E Dahlberg; A Thalén; R Brattsand; J A Gustafsson; U Johansson; K Roempke; T Saartok
Journal:  Mol Pharmacol       Date:  1984-01       Impact factor: 4.436

8.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

9.  Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.

Authors:  Stephen B Hanauer; Burton I Korelitz; Paul Rutgeerts; Mark A Peppercorn; Ronald A Thisted; Russell D Cohen; Daniel H Present
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

Review 10.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

View more
  4 in total

Review 1.  Indications and surgical options for small bowel, large bowel and perianal Crohn's disease.

Authors:  James Wt Toh; Peter Stewart; Matthew Jfx Rickard; Rupert Leong; Nelson Wang; Christopher J Young
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

Review 2.  Medical Management of Crohn's Disease.

Authors:  Ajay K Gade; Nathan T Douthit; Erin Townsley
Journal:  Cureus       Date:  2020-05-29

Review 3.  A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease.

Authors:  Seyed Saeid Seyedian; Forogh Nokhostin; Mehrdad Dargahi Malamir
Journal:  J Med Life       Date:  2019 Apr-Jun

4.  TWEAK/Fn14 Is Overexpressed in Crohn's Disease and Mediates Experimental Ileitis by Regulating Critical Innate and Adaptive Immune Pathways.

Authors:  Luca Di Martino; Abdullah Osme; Sarah Kossak-Gupta; Theresa T Pizarro; Fabio Cominelli
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.